Movement Alert｜Zai Lab Rises 5.46% in Regular Trading, Biotech Sector Rally Drives Oversold Rebound

Market Focus06-23

On June 23, Zai Lab rose 5.46% in regular trading, trading at 14.67 HKD/share, with turnover of 33.80 million HKD.

On the news front, the biotechnology sector saw broad-based strength, with AKESO up 6.51%, Remegen up 5.47%, Innovent Bio up 4.78%, and BeiGene up 4.22%, creating a significant sector linkage effect. The rally carries characteristics of an oversold rebound, as Zai Lab dropped over 5% the previous session after partner Novocure announced that its tumor treating fields therapy TTFields failed to meet the overall survival primary endpoint in the Phase III TRIDENT trial for newly diagnosed glioblastoma, with mOS of 17.7 months versus 17.5 months (HR=0.953, p=0.519). Zai Lab holds Greater China rights to TTFields, marketed domestically under the OPTUNE brand, which contributed approximately 48 million USD in sales in 2025.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198032924?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 09:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198032924","market":"us","top_or_hot":-1,"title":"Movement Alert｜Zai Lab Rises 5.46% in Regular Trading, Biotech Sector Rally Drives Oversold Rebound","media":"Market Focus","content":"<p><p>On June 23, Zai Lab rose 5.46% in regular trading, trading at 14.67 HKD/share, with turnover of 33.80 million HKD.</p><p>On the news front, the biotechnology sector saw broad-based strength, with AKESO up 6.51%, Remegen up 5.47%, Innovent Bio up 4.78%, and BeiGene up 4.22%, creating a significant sector linkage effect. The rally carries characteristics of an oversold rebound, as Zai Lab dropped over 5% the previous session after partner Novocure announced that its tumor treating fields therapy TTFields failed to meet the overall survival primary endpoint in the Phase III TRIDENT trial for newly diagnosed glioblastoma, with mOS of 17.7 months versus 17.5 months (HR=0.953, p=0.519). Zai Lab holds Greater China rights to TTFields, marketed domestically under the OPTUNE brand, which contributed approximately 48 million USD in sales in 2025.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Zai Lab Rises 5.46% in Regular Trading, Biotech Sector Rally Drives Oversold Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Zai Lab Rises 5.46% in Regular Trading, Biotech Sector Rally Drives Oversold Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-23 09:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 23, Zai Lab rose 5.46% in regular trading, trading at 14.67 HKD/share, with turnover of 33.80 million HKD.</p><p>On the news front, the biotechnology sector saw broad-based strength, with AKESO up 6.51%, Remegen up 5.47%, Innovent Bio up 4.78%, and BeiGene up 4.22%, creating a significant sector linkage effect. The rally carries characteristics of an oversold rebound, as Zai Lab dropped over 5% the previous session after partner Novocure announced that its tumor treating fields therapy TTFields failed to meet the overall survival primary endpoint in the Phase III TRIDENT trial for newly diagnosed glioblastoma, with mOS of 17.7 months versus 17.5 months (HR=0.953, p=0.519). Zai Lab holds Greater China rights to TTFields, marketed domestically under the OPTUNE brand, which contributed approximately 48 million USD in sales in 2025.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"","article_id":"1198032924","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198032924","pubTimestamp":1782179568,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 23, Zai Lab rose 5.46% in regular trading, trading at 14.67 HKD/share, with turnover of 33.80 million HKD.On the news front, the biotechnology sector saw broad-based strength, with AKESO up...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09688":"再鼎医药"},"translate_title":"动向提示|再鼎医药常规交易涨5.46%生物科技板块涨势带动超跌反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1},"content_text":"On June 23, Zai Lab rose 5.46% in regular trading, trading at 14.67 HKD/share, with turnover of 33.80 million HKD.On the news front, the biotechnology sector saw broad-based strength, with AKESO up 6.51%, Remegen up 5.47%, Innovent Bio up 4.78%, and BeiGene up 4.22%, creating a significant sector linkage effect. The rally carries characteristics of an oversold rebound, as Zai Lab dropped over 5% the previous session after partner Novocure announced that its tumor treating fields therapy TTFields failed to meet the overall survival primary endpoint in the Phase III TRIDENT trial for newly diagnosed glioblastoma, with mOS of 17.7 months versus 17.5 months (HR=0.953, p=0.519). Zai Lab holds Greater China rights to TTFields, marketed domestically under the OPTUNE brand, which contributed approximately 48 million USD in sales in 2025.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198032924","isCrawlerRequest":true}